Rafał Filip

机构：University of Rzeszów · ORCID：0000-0002-5954-151X

发表论文 193 篇 · 总被引 3904 次 · h-index 29

代表论文

• Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (2024 · The Lancet · 被引 109)
• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 95)
• Transplant of microbiota from Crohn’s disease patients to germ-free mice results in colitis (2024 · Gut Microbes · 被引 47)
• Nitrate and Nitrite in the Diet: Protective and Harmful Effects in Health and Disease (2025 · Current Nutrition Reports · 被引 23)
• Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (2025 · Medicina · 被引 19)
• Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis? (2024 · International Journal of Molecular Sciences · 被引 19)